SAN DIEGO, Feb. 24 /PRNewswire-FirstCall/ -- CryoCor, Inc. , a medical device company focused on the treatment of cardiac arrhythmias, announced today that Gregory J. Tibbitts, Chief Financial Officer and Vice President of Finance, is scheduled to present at The Wall Street Analyst Forum Analyst Conference, February 28, 2006 at 2:40 p.m. ET at The Princeton Club in New York City.
A live Web cast and recording of the presentation will be available online from the investor relations page of the Company's corporate Web site at http://ir.cryocor.com. The recording will remain available on CryoCor's Web site until March 30, 2006.
About CryoCor
CryoCor is a medical technology company that has developed and manufactures a disposable catheter system based on its proprietary cryoablation technology for the minimally invasive treatment of cardiac arrhythmias. The Company's product, the CryoCor Cardiac Cryoablation System, is designed to treat cardiac arrhythmias through the use of cryoenergy, or extreme cold, to destroy targeted cardiac tissue. The CryoCor System has been approved in Europe for the treatment of atrial fibrillation and atrial flutter, the two most common and difficult to treat arrhythmias, since 2002. In the United States, CryoCor is conducting a pivotal trial to evaluate the safety and efficacy of the CryoCor Cardiac Cryoablation System for the treatment of atrial fibrillation. In addition, the Company has conducted a pivotal trial for the treatment of atrial flutter and filed a PMA with the FDA in 2005. The FDA did not approve that PMA filing for the treatment of atrial flutter and CryoCor is evaluating its ability to amend the PMA. For more information please visit the Company's website at http://www.cryocor.com.
Forward Looking Statements
The statements in this press release that are not descriptions of historical facts are forward-looking statements that are subject to risks and uncertainties. These include statements related to CryoCor's proposed amendment to its PMA for atrial flutter, its expectations for its burn rate during 2006, including the timing for reductions therein, the Company's expected cash reserves at the end of 2006 and its ability to finance itself without raising additional funding through 2007, the Company's repayment of its existing debt in 2007, the Company's need for and ability to access additional financing, the Company's projected 2006 revenues, and the other financial guidance included in this press release, all of which are prospective. Such statements are only predictions and reflect the Company's expectations and assumptions as of the date of this press release based on currently available operating, financial, and competitive information. The actual events or results may differ materially from those projected in such forward-looking statements due to a number of factors, including risks involved with the Company's ability to reduce its cash burn as much as it anticipates within the timeframes it anticipates and otherwise meet its financial guidance, access additional financing when and to the extent necessary and obtain regulatory approval in the United States for its Cardiac Cryoablation System for use in treating atrial flutter and atrial fibrillation within its anticipated timeframes, if at all; risks associated with the Company's ability to add additional clinical sites for and complete enrollment in its atrial fibrillation pivotal trial and submit a PMA for atrial fibrillation; risks associated with the Company's ability to amend its PMA for atrial flutter and ultimately receive approval from the FDA for the use of its Cryoablation System to treat atrial flutter; risks associated with the Company's ability to successfully commercialize its Cardiac Cryoablation System in the United States and elsewhere if its Cardiac Cryoablation System is approved for use in the United States; risks associated with the Company's dependence on patents and proprietary rights; risks associated with the Company's protection and enforcement of its patents and proprietary rights; risks associated with the development or availability of competitive products or technologies; and the other risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. These forward- looking statements speak only as of the date hereof. The Company expressly disclaims any intent or obligation to update any of these forward-looking statements.
Contact: CryoCor The Ruth Group Gregory J. Tibbitts Stephanie Carrington / Chief Financial Officer Nick Laudico (investors) (858) 909-2200 (646) 536-7017 / 7030 gtibbitts@cryocor.comscarrington@theruthgroup.comnlaudico@theruthgroup.com Jason Rando (media) (646) 536-7025 jrando@theruthgroup.com
CryoCor, Inc.CONTACT: Gregory J. Tibbitts, Chief Financial Officer of CryoCor, Inc.,+1-858-909-2200, gtibbitts@cryocor.com; or Stephanie Carrington,+1-646-536-7017, scarrington@theruthgroup.com, or Investors - Nick Laudico,+1-646-536-7030, nlaudico@theruthgroup.com, or Media - Jason Rando,+1-646-536-7025, jrando@theruthgroup.com, all of The Ruth Group, forCryoCor, Inc.
